1-19-21 China’s drug authority approved China’s first gene-editing therapy clinical trial . The approved gene-editing product et-01 , developed by Edigene Inc. 博雅辑因(北京)科技有限公司 , a Zhongguancun biomedical enterprise in Beijing, was for blood transfusion dependent β – thalassemia 地中海型贫血.
这种技术叫做：β地中海贫血的基因组编辑治疗。它运用基因组编辑技术，对病人的造血干细胞重新编辑，从而改进造血功能。这项治疗技术目前在世界上只有极少企业在做，而中国仅此一家。
